Mayo Clinic Study: Menopause Symptoms Cost $1.8 Billion in Lost Work Time Annually

Published in Mayo Clinic Proceedings in April 2023, this study is one of the first to put a dollar figure on how menopause symptoms affect women in the American workforce. Researchers surveyed 4,440 employed women aged 45 to 60 receiving primary care at Mayo Clinic sites and found that 13.4% reported at least one adverse work outcome directly attributable to menopause symptoms. More than 10% reported missing work in the preceding year, with a median of three days lost. Extrapolated nationally across nearly 50 million women in the U.S. labor force who fall within the affected age range, the estimated cost is $1.8 billion per year in lost work time alone — and $26.6 billion annually when medical expenses are included.

The dose-response relationship was stark: women in the highest quartile of menopause symptom severity were 15.6 times more likely to report adverse work outcomes — including reduced performance, absenteeism, and career-limiting decisions like declining promotions or considering early retirement — compared to women with mild symptoms. The findings echo a 2025 Stanford study by economist Petra Persson, which documented significant earnings declines among menopausal women and found that menopause can push women into permanent workforce exit through disability claims and early retirement.

Why This Matters

The economic data makes the clinical argument impossible to ignore: untreated or under-treated menopause symptoms have measurable consequences that extend beyond the individual to employers and the broader economy. But the solution is not just awareness — it is action, and action requires information. Women who can show their employer or clinician a documented pattern of symptoms, their severity, and their correlation with work impact have a fundamentally different conversation than women who say "I think menopause is affecting my work." Symptom tracking transforms a vague concern into evidence. For employers developing menopause policies and for women advocating for their own care, that evidence is the starting point for meaningful support.